Biomarker-guided dose selection in the iintune-1 study of dazostinag,a STING agonist, alone and in combination with pembrolizumab for patients with metastatic solid tumors

Publication Title

AACR Annual Meeting April 25-30; Chicago, IL. 2025: LB397/3

Document Type

Presentation

Publication Date

4-2025

Keywords

oregon; chiles

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Comments

Ramesh R, Ding K, Tong X, Xu R, Perera S, Appleman V, Sheykin Y, Li C, Luke JJ, Gao X, Olszanski AJ, Sanborn RE, Falchook GS, Patel SP, Bedard PL, Orr DW, LoRusso P, Huang H, Raizer J, Gibbs J, Lineberry N, Gregory RC.

This document is currently not available here.

Providence Full Text

Share

COinS